Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. ... Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Contact Us. Alnylam is leading the translation of RNA interference (RNAi) into an innovative new class of medicines for patients who have limited or inadequate treatment options. Since 2002, Dr. John Maraganore has served as the CEO and a Director of Alnylam. Kärntner Ring 5-7 Alnylam Austria GmbH. For inquiries or to request additional information, we can be reached by email or calling our corporate headquarters. Alnylam Pharmaceuticals Cambridge. 675 West Kendall St Cambridge, MA 02142 Tel: 617.551.8200 Fax: 617.551.8101. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in “@alnylam.com.” Please do not provide any personal information if you receive a suspicious inquiry or job offer. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals… Alnylam Pharmaceuticals Email Format Alnylam Pharmaceuticals uses 6 email formats, with … The following content may not be associated with Alnylam Pharmaceuticals. Receive news and updates on the work at Alnylam that affects you most. Proceed to Site × For inquiries or to request additional information, Alnylam can be reached by email or by calling the company's corporate headquarters. John Maraganore, P h D Chief Executive Officer. Alnylam to Webcast Presentations at Upcoming May Investor Conferences: May 06, 2020: Alnylam Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Period Activity: May 04, 2020: Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19 SIGN UP FOR EMAIL UPDATES. Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.